![](https://img.einpresswire.com/small/665321/sarcomatrix-therapeutics-corp.png)
Sarcomatrix Therapeutics Secures Exclusive License Rights for Groundbreaking Muscle-Stabilizing and Regenerating Drugs
Innovative Treatments Targeting Muscular Dystrophies, Cachexia, and Sarcopenia to Transform the Future of Muscle-Wasting Disease Therapy RENO, NV, UNITED STATES, July 8, 2024 /EINPresswire.com/ -- Sarcomatrix Therapeutics Corp., a pioneering biotech …